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Abstract
Background: This study of the oropharyngeal microbiome complements the previously published AZIthromycin in
Severe ASThma (AZISAST) clinical trial, where the use of azithromycin was assessed in subjects with exacerbation-
prone severe asthma. Here, we determined the composition of the oropharyngeal microbial community by means
of deep sequencing of the amplified 16S rRNA gene in oropharyngeal swabs from patients with exacerbation-
prone severe asthma, at baseline and during and after 6 months treatment with azithromycin or placebo.
Results: A total of 1429 OTUs were observed, of which only 59 were represented by more than 0.02% of the reads.
Firmicutes, Bacteroidetes, Fusobacteria, Proteobacteria and Actinobacteria were the most abundant phyla and
Streptococcus and Prevotella were the most abundant genera in all the samples. Thirteen species only accounted for
two thirds of the reads and two species only, i.e. Prevotella melaninogenica and Streptococcus mitis/pneumoniae,
accounted for one fourth of the reads.
We found that the overall composition of the oropharyngeal microbiome in patients with severe asthma is
comparable to that of the healthy population, confirming the results of previous studies. Long term treatment
(6 months) with azithromycin increased the species Streptococcus salivarius approximately 5-fold and decreased the
species Leptotrichia wadei approximately 5-fold. This was confirmed by Boruta feature selection, which also
indicated a significant decrease of L. buccalis/L. hofstadtii and of Fusobacterium nucleatum. Four of the 8 treated
patients regained their initial microbial composition within one month after cessation of treatment.
Conclusions: Despite large diversity of the oropharyngeal microbiome, only a few species predominate. We
confirm the absence of significant differences between the oropharyngeal microbiomes of people with and
without severe asthma. Possibly, long term azithromycin treatment may have long term effects on the composition
of the oropharygeal microbiome in half of the patients.
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Background
Asthma is a chronic disease of the airways, character-
ized by chronic airway inflammation and variable
symptoms of wheezing, dyspnea and cough [1]. The
genetic and environmental factors that determine
asthma are not well understood, but several studies
suggest that microbes from oral sites not only con-
tribute to colonization of the airways in disease (as in
cystic fibrosis) [2–4], but also that microbial
colonization of the airways might have a role in the
chronic inflammatory process [1, 5]. For instance, both
Chlamydophila pneumoniae and Mycoplasma pneumo-
niae have been detected in respiratory secretions from pa-
tients with acute asthma exacerbations [6–8].
Recently, the macrolides erythromycin and azithromy-
cin have been assessed as an addition to standard ther-
apy to prevent exacerbations in patients with asthma or
chronic obstructive pulmonary disease (COPD) [9–13].
Macrolides exert their antimicrobial effects by binding
to the 50S ribosomal RNA subunit and have a broad
spectrum of activity against many micro-organisms [14].
In addition, macrolides have multiple immunomodula-
tory and anti-inflammatory effects [12, 15]. However,
use of antibiotics has been associated with the develop-
ment of antimicrobial resistance of bacteria in individual
patients and at population level. Although the induction
of antimicrobial resistance has been investigated in
healthy individuals after short-term administration of
macrolides, the effects of chronic treatment with macro-
lides on the composition of the pharyngeal microbiome
in patients with (severe) asthma remain to be elucidated.
In this study, we determined the composition of the
oropharyngeal microbial community by means of deep se-
quencing of the amplified 16S rRNA gene in oropharyn-
geal swabs from patients with exacerbation-prone severe
asthma at baseline and during treatment with azithromy-
cin or placebo for 6 months. Samples had been collected
during the AZIthromycin in Severe ASThma (AZISAST)
randomized controlled clinical trial (RCT) [12].
Methods
Study background
This study of the oropharyngeal microbiome comple-
ments a previously reported clinical study, i.e. the AZI-
thromycin in Severe ASThma (AZISAST) trial [12],
which was a randomized, double-blind, placebo-
controlled, parallel-group multicenter study in subjects
with exacerbation-prone severe asthma. Severe asthma
was defined as in the European Respiratory Society and
American Thoracic Society Severe Asthma guidelines
[16], i.e., adult patients with asthma, needing treatment
with high dose inhaled corticosteroids (ICS) and long-
acting beta2-agonists (LABA) (thus Global Initiative for
Asthma - GINA - guideline step 4 or 5), who still had
experienced two or more exacerbations in the previous
year despite this maintenance treatment. Moreover, the
diagnosis of severe asthma was made by a respiratory
physician. During the selection of the patients (See
Table 1 for patient characteristics), the exacerbation and
smoking history were taken into account (See Additional
file 1 for the AZISAST-trial baseline characteristics
[12]). A medical history of at least two exacerbations
(treated with oral corticosteroids) in the previous year
was an inclusion criterion. Current smoking or a smok-
ing history of more than 10 pack years were exclusion
criteria of the AZISAST study. The majority of patients
were never smokers; ex-smokers had smoked less than
10 pack years, and had stopped smoking for at least one
year.
The AZISAST study including this bacteriological sub-
study was approved by the central ethics committee of
Ghent University Hospital, and was reviewed by the
local ethics committees at each participating site (2008/
445, IWT 070709). All patients provided written in-
formed consent.
The oropharyngeal samples for the bacteriologic sub-
study of the AZISAST trial were obtained in two centers
(Ghent University Hospital and OLV Hospital Aalst).
For this study and manuscript, only samples of patients
enrolled at Ghent University Hospital were examined, in
order to minimize heterogeneity due to differences in
sampling techniques. Indeed, all oropharyngeal samples
at Ghent University Hospital were taken by one experi-
enced study nurse using a standardized procedure.
Briefly, during the AZISAST study, the subjects re-
ceived low-dose azithromycin (n = 55) or placebo (n =
54) as an add-on treatment to combination therapy of
inhaled corticosteroids and long-acting β2 agonists for
6 months. After randomization, patients took one cap-
sule of 250 mg azithromycin (prepared from capsules of
Zithromax) or placebo once daily for 5 days and then
one capsule of 250 mg azithromycin or placebo three
times a week. The total treatment period was 26 weeks
(until visit 6), with a study drug-free follow-up period of
4 weeks (washout period) [12].
Study design
We included three groups of patients in the bacterio-
logical substudy, i.e. 5 subjects of the placebo group and
8 azithromycin (AZ)-treated patients encompassing 5
AZ responders and 3 AZ non-responders. The AZ re-
sponders were patients in the active treatment arm (azi-
thromycin) who had a more than 50% decrease in the
rate of the primary outcome (i.e. asthma exacerbations)
during the treatment phase of the AZISAST trial com-
pared to the previous year (i.e. the year before enroll-
ment in the trial).
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The oropharyngeal microbiome was assessed at
four different visits during the trial, i.e. at visit 2
(V2): at randomization (just before treatment), at
visit 3 (V3): one month after the start of treatment,
at visit 6 (V6): at the end of the 6 months treatment
period and at visit 7 (V7): one month after the end
of the treatment period (i.e. at the end of the wash-
out period).
Sample collection
Although sputum (spontaneous or induced), bronchial
brushings or bronchoalveolar lavage samples could pos-
sibly demonstrate more pronounced effects of azithro-
mycin treatment, these samples are more difficult to
obtain, and invasive techniques (such as bronchoscopy
for bronchial brushings or lavage) could induce asthma
attacks in patients with severe asthma. Therefore, we





Sex (no. of subjects)
Male 3 (60%) 3 (38%)
Female 2 (40%) 5 (62%)
Age (yr)
Median, Range, IQR 57 (41;64), (48;62) 48 (19;60), (40;52)
Race (no. of subjects; %)
Caucasian 5 (100%) 8 (100%)
Body-mass index
Mean (SD) 31.5 (5.5) 26.0 (5.9)
Positive atopic status
(no. of subjects; %)* 3 (60%) 6 (75%)
Severe asthma exacerbations requiring treatment with systemic corticosteroids
previous 12 months (% of subjects) 5 (100%) 6 (75%)
previous 12 months (no. [mean], SD) 2.2 (0.4) 1.9 (1.5)
Lower respiratory tract infections requiring treatment with antibiotics
previous 12 months (% of subjects) 4 (80%) 6 (75%)
previous 12 months (no. [mean], SD) 1.0 (0.7) 2.8 (1.9)
FEV1 prebronchodilator (% of predicted)
Mean (SD) 87.6 (19.1) 87.9 (19.0)
FEV1/FVC ratio prebronchodilator
Mean (SD) 60.4 (12.1) 66.9 (9.4)
FENO (ppb)
Median, Range, IQR 12.8, (8;26.7), (10;20.9) 30, (13;54), (20.3;37.5)
Eosinophil count in blood (x10-9/liter)
Mean (SD) 494.0 (420.9) 161.3 (100.2)
Daily dose of inhaled corticosteroid (BDP-equivalent) (μg)
Daily dose 2000, (2000;3000), 2125, (1500;4000),
Median, Range, IQR (2000;2500) (2000;3625)
Use of oral prednisolone
Regular use (% of subjects) 1 (20%) 2 (25%)
Daily maintenance dose (mg)
Median, Range, IQR 2.5, (−;-), (−;-) 8.8, (7.5;10), (−;-)
Use of montelukast (leukotriene receptor antagonsist) (no. of subjects; %) 2 (40%) 2 (25%)
Legend: *Atopic status: based on skin prick tests; if skin prick test was not interpretable or not available, the atopic status is based on serum RAST for standard
aero-allergens (house dust mite, animal dander [cat, dog], pollen [grass, tree] and Aspergillus fumigatus)
Abbreviations: ACQ asthma control questionnaire, AQLQ asthma quality of life questionnaire, BDP beclomethasone dipropionate, IQR interquartile range, LRT lower
respiratory tract
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have chosen to sample the oropharynx, since this sam-
pling technique is well tolerated and safe, and could be
performed at four different visits in all patients (in the
two centers who participated in the AZISAST sub
study). Moreover the oropharynx can be regarded as the
best proxy for the lung microbiome [17–21].
Briefly, oropharyngeal samples were obtained by
means of a swab firmly pressed over the tonsils and the
posterior pharyngeal wall [22]. The jaws, teeth and gin-
giva were avoided when the swab was withdrawn.
DNA extraction and sequencing
For DNA extraction, the oropharyngeal swab was
immersed in physiological water and a volume of 200 μl
of the suspension was transferred to a 2 ml tube, to
which 200 μl of buffer (20 mM Tris–HCl, pH 8.0, 0.5%
Sodium dodecyl sulfate) was added. Subsequently, 2 μl
of mutanolysin (25 U/μl) was added and the mixture
was incubated for 15 min at 37 °C. Next, 10 μl of a
25 mg/ml proteinase K solution was added and the mix-
ture was incubated for 15 min at 55 °C. Finally, Nucli-
SENS EasyMAG lysis buffer was added to a final volume
of 2 ml, and incubated for 10 min at room temperature.
DNA extraction was performed on the NucliSENS Easy-
MAG (BioMérieux, Marcy l’Etoile, France) platform, ac-
cording to the manufacturer’s instructions.
The bacterial 16S rRNA gene was amplified, starting
from 25–100 ng of DNA template in the presence of
0.2 μM of the 27 F forward primer (AGAGTTT
GATCMTGGCTCAG) and an equimolar mixture of the
reverse primers 338R-B-I (GCWGCCTCCCGTAG
GAGT) and 338R-B-II (GCWGCCACCCGTAGGTGT)
(to compensate for mismatches), specific for the V1-V2
hypervariable region of the bacterial 16S rRNA gene
[23]. The forward primer had an adaptor sequence and a
unique barcode sequence, i.e. MID (Multiplex IDenti-
fier), to help identify the samples after sequencing. PCR
products were visualized on agarose gel and purified
using a double purification protocol with AMpure XP
DNA-binding magnetic beads (Agencourt, Beckman
Coulter, Woerden, the Netherlands), and quantified in
triplicate, using the Qubit 2.0 dsDNA HS Assay (Life
Technologies, Ghent, Belgium). Samples were then di-
luted to a concentration of 1 × 109 molecules/μL and
equimolar concentrations of 10 samples were pooled to
create a multiplexed amplicon library. This amplicon li-
brary was purified again using a double purification
protocol with AMpure XP DNA-binding magnetic
beads. The library was further diluted to 106 molecules/
μl and subjected to emulsion PCR (emPCR – 35 PCR
cycles instead of 50 cycles) using the 454 GS Junior
Titanium Series Lib-L emPCR Kit (Roche Diagnostics,
Vilvoorde, Belgium) and the Live Amp Mix B for Paired
End libraries, according to the manufacturer’s protocols.
After the emPCR, the DNA-bound beads were enriched
with a second DNA capture mechanism to separate the
beads with bound emPCR products from the empty
beads. Using a bead counter, the number of enriched
beads was estimated to be 500,000. The enriched pool of
beads was then used for massive parallel pyrosequencing
in a Titanium PicoTiterPlate with Titanium reagents
(Roche Diagnostics), on the GS Junior instrument (454
Life Sciences, Branford, Connecticut), according to the
454 GS Junior Titanium Series Amplicon Library Prep-
aration Method Manual.
Sequence analysis
The Roche Amplicon filter pipeline was used for quality-
filtering of the amplicons and for generating the Stand-
ard flowgram format (sff )-files. For the analysis of the
sequencing data, the Genboree Microbiota Toolset was
used as described by Riehle et al. [24, 25]. This toolset
has integrated open source tools for 16S rRNA gene
analyses, such as the Ribosomal Database Project (RDP)
classifier [26] and QIIME (Quantitative Insights Into Mi-
crobial Ecology) [27].
The Genboree Workbench was used to upload the se-
quencing sff-files for each sample together with the asso-
ciated sample metadata. Individual sequencing files were
passed through a quality filtering algorithm that used
the following filter read settings: Trim at distal primer,
remove sequences with ambiguous nucleotides, mini-
mum read length of 300 nt, minimum average quality
score = 20 and minimum sequence count per sample =
1000. Subsequently, Operational Taxonomic Units
(OTU) generation and analyses of alpha diversity and
beta diversity, phylogenetic analysis, and feature selec-
tion were performed [24].
Briefly, OTU generation was accomplished by a multi-
step OTU picking algorithm that generates representa-
tive sequences, whereby similar sequences are binned
together into the same OTU, and produces an OTU
table as a result. The OTU tables were used for down-
stream analyses, such as alpha diversity and beta diver-
sity calculation, classification by supervised machine
learning, and feature selection [24]. Beta diversity clus-
tering plots (via Principal Coordinates Analysis (PcoA))
were generated using the phylogenetic unweighted Uni-
Frac metric to determine the differences between the
different clinical metadata groups [24, 28]. To confirm
actual clustering of microbiomes on the basis of treat-
ment (azithromycin vs. placebo) or on the basis of differ-
ent visits, supervised learning with randomForest
classification [24, 29] was used, with the assumption that
if randomForest generated an estimated error rate of <
5%, it could be claimed that these clinical metadata
groups contain significantly different microbial commu-
nities. In case of estimated error rates greater than 10%,
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Boruta feature selection still can be used to obtain statis-
tically significant features [24, 30, 31]. In the supervised
machine learning analyses, i.e. randomForest and Boruta
feature selection, cut off values based on the sum of the
rows in the OTU table were deployed for a variety of
reasons, but mainly to remove noise and to decrease the
time and resource requirements to run randomForest
and Boruta. Removing low abundant OTUs has been
found to increase the success of classifying (randomFor-
ests) and feature selection (Boruta) by decreasing the
noise of the microbial community data representation. A
range of cut off values, i.e. 5, 25, 100 and 500, was used
to vary the degree of noise removal. For instance, a cut
off value of 5 indicates that the OTUs (i.e. rows) from
the OTU table that do not sum up to at least 5 reads are
not taken into account [24, 31]. This allows to increase
the weight of the highly abundant OTUs. The Human
Oral Microbiota Database (HOMD [32], which provides
a curated, full length, 16S rRNA gene reference data set
[33, 34], was used to get an idea of which species the
OTUs possibly represented. Species level identification
was obtained through the HOMD Blast search tool, with
a minimum alignment requirement of 97% with the
query sequence [32]. Each species-level identified OTU




Recently, Brusselle et al. [12] reported that patients with
severe asthma and non-eosinophilic inflammation (nor-
mal Fractional exhaled nitric oxide-FeNO and blood eo-
sinophilia < 200/μL) had a significant reduction of
exacerbation rate upon treatment with low dose azithro-
mycin (AZ) for 6 months, compared with the placebo
arm (AZISAST trial). In contrast, patients with severe
asthma and eosinophilic inflammation (blood eosino-
philia > 200/μL) did not benefit from AZ treatment com-
pared with placebo [12]. In the AZISAST-trial, bacterial
cultures were performed on the oropharyngeal samples
used in the present study, demonstrating an increased
resistance of oropharyngeal streptococci to macrolides
in the azithromycin-treated patients [12].
In this microbiological substudy of the AZISAST trial,
we carried out a cross-sectional and longitudinal evalu-
ation of the oropharyngeal microbiomes of the AZ-
treated and placebo-treated groups by means of a
cultivation-independent manner using next-generation
sequencing of amplified 16S rRNA genes. We studied
three groups of asthmatic patients, i.e. azithromycin
(AZ) responders (n = 5; patients 106, 115, 126, 129 and
142), AZ non-responders (n = 3; patients 110, 122 and
151) and patients receiving placebo (n = 5; patients 101,
104, 111, 112 and 121).
We established the composition of the oropharyngeal
microbiome and studied to what extent long term azi-
thromycin treatment influenced the microbial compos-
ition of the oropharynx.
Overall analysis
A total of 473.995 reads were obtained for 52 oropha-
ryngeal samples (4 sampled visits from each of 13
subjects), of which 466.401 reads passed quality filter-
ing. On average, there were 8.969 quality filtered
reads per sample (range: 2.653–25.809 reads). All se-
quences are available at National Center for Biotech-
nology Information (NCBI) Bioproject with identifier
PRJNA356972 [35].
Overall, a total of 1429 OTUs were recognized. Of
these, only 59 (4%) were represented by 0.2% or more of
the reads, accounting for 89.75% of all the reads (Add-
itional file 2). Most of these 59 OTUs correspond to
HOMD Human Oral Taxons (HOTs), i.e., species with
familiar names in oral microbiology [34], but some of
these species, such as Lachnoanaerobaculum orale
(0.37% of overall number of reads), Lautropia mirabilis
(0.46%), Megasphaera micronuciformis (0.72%), Oribac-
terium sinus (0.57%), Solobacterium moorei (0.36%) and
genus TM7 [G-1] sp. (0.38%) from the phylum Sacchari-
bacteria, are not as well-known. On the other hand, spe-
cies such as Haemophilus influenzae and Moraxella
catarrhalis, well-known inhabitants and potential patho-
gens of the upper airways, were virtually absent. M. cat-
arrhalis was found in only one sample (Patient 106 Visit
2), representing only 0.06% of the reads of that sample.
H. influenzae was present in 17 samples (7 V2 samples,
5 V3 samples and 5 V7 samples), but represented on
average only 0.02% of the reads per sample (range 0.01–
0.07%). The only exception was Haemophilus parainfluen-
zae, a potential pathogen and common inhabitant of the
oropharynx, accounting for 2.11% of the reads. The pres-
ence or absence of Streptococcus pneumoniae is difficult
to establish, because of the high similarity with the closely
related commensal S. mitis (accounting for 10.68% of the
reads) in the V1-V2 region that was sequenced for this
study. No reads for Chlamydophila pneumoniae or
Mycoplasma pneumoniae were present among the asthma
patients, although M. faucium, M. lipophilum and M.
salivarium were recovered in low numbers.
Moreover, only 13 species (HOTs) accounted for 65.03%
of the reads, i.e.: Prevotella melaninogenica (HOT-469;
15.17%), Streptococcus mitis/pneumoniae (HOT-677;
10.68%), Streptococcus parasanguinis (HOT-411; 6.84%),
Veillonella atypica (HOT-524; 5.41%), Streptococcus sali-
varius (HOT-755; 4.13%), Leptotrichia wadei (HOT-222;
3.86%), Granulicatella adiacens (HOT-534; 3.85%), Fuso-
bacterium periodonticum (HOT-201; 3.01%), Neisseria fla-
vescens (HOT-610; 2.94%), Gemella sanguinis (HOT-757,
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2.60%), Actinomyces graevenitzii (HOT-866; 2.45%), Hae-
mophilus parainfluenzae (HOT-718; 2.11%) and Prevotella
pallens (HOT-714; 1.99%).
In summary, a total of 1429 OTUs were observed of
which only 59 were represented by more than 0.02% of
the reads, with eleven of these 59 mainly present in only
one or two patients (Additional file 2 – grey colored
cells) and 13 accounting for 65.03% of the reads.
Comparison of the oropharyngeal microbial composition
of the non-AZ-treated and AZ-treated patients
Beta diversity analysis, using the phylogenetic-based un-
weighted UniFrac algorithm Principal Coordinates Ana-
lysis, was applied to examine qualitative differences
between the oropharyngeal microbiomes, based on pres-
ence or absence of OTUs in the non-AZ-treated samples
(all 20 samples from the 5 placebo-receiving patients +
V2 samples of the 8 AZ-treated patients, n = 28) versus
the AZ-treated samples (visits V3 and V6 of the 8 AZ-
treated patients, n = 16) (Fig. 1).
The oropharyngeal microbiomes of the AZ-treated
samples clustered together (Fig. 1 and Additional file 3).
Not only did the oropharyngeal microbiome of each
treated patient shift to the left for Principal Coordinate 1
(capturing 14.44% of the variation) after the AZ treat-
ment, the microbiomes of the AZ-treated samples also
shifted closer to one another, which indicates that shared
changes occurred for the treated samples. However, ran-
dom Forest classification estimated error indicated that
the treated and untreated samples were not significantly
different from each other, because the estimated error
rates were greater than 5% (Table 2).
Fig. 1 also shows that several of the samples from the
5 placebo-receiving subjects (101, 104, 111, 112 and
121), whereby all of the samples represent untreated
oropharyngeal microbiomes, cluster closely together per
patient, indicating that the changes that are observed for
the treated patients are not likely the result of random
temporal changes in the oropharyngeal microbiome that
could have occurred during the study period.
In addition, Fig. 2 shows that, for the 8 treated pa-
tients, 4 out of the 8 V7 samples (sampled one month
after treatment) are more proximal to the untreated
samples (V2) of the same patient than the during
Fig. 1 Beta diversity analysis of the oropharyngeal microbiomes of non-azithromycin-treated samples and azithromycin-treated samples. Legend:
The Principal Coordinates Analysis plot using the phylogenetic-based unweighted UniFrac algorithm for the comparison of the oropharyngeal
microbiomes of the non- azithromycin (AZ)-treated samples with the oropharyngeal microbiomes of the AZ-treated samples. Blue dots: non-AZ-
treated samples (n = 28): all samples of the 5 placebo-receiving subjects (n = 20) + the V2 samples of the 8 AZ-treated subjects. Green dots: AZ-
treated samples (n = 16): V3 and V6 samples of the 8 AZ-treated patients. Each group of dots of the same patient is labeled with the
patient number
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treatment samples V3 and V6, although the time lapse
between V7 and V2 samples is larger than between V7
and V3-V6 samples. This similarity between pre- (V2)
and post-treatment (V7) samples is suggestive of recov-
ery of the original microbiome.
When looking at the taxonomic composition of the
microbiomes at the phylum level (Fig. 3), Firmicutes,
Bacteroidetes, Fusobacteria, Proteobacteria and
Actinobacteria appear to be the most abundant phyla,
with little difference between the treated, untreated
and washout samples. Fusobacteria decrease and Fir-
micutes increase after the start of and during AZ
treatment, but their numbers virtually equal the pre-
treatment status (V2) after a one month washout
period (V7). It can be noticed that the phylum Tener-
icutes (more specifically the genus Mycoplasma)
Table 2 Supervised (machine) Learning Estimated Error Rates (randomForest simulation) for abundant OTU denoised pipelines
Clinical characteristic Minimal Row Contribution Cut Off Sum for Each OTU
5 25 100 500
Estimated Error Rate (%)
Treatment
(i.e. AZ-treated and non-treated)
15.91 13.64* 15.91 18.18
Visit
(i.e. V2, V3, V6 and V7)





22.73 25.0 20.45 20.45
Legend: Estimated error rate of the randomForest simulation by virtue of potentially contributable clinical metadata (Treatment, visit and Patient group) following
an abundant OTU pipeline for denoising of dataset, i.e. following removal of chimeric and low quality sequences. Top row header: Minimal row contribution cut
off sum for each OTU to determine the best performing data set (i.e. contains the most discriminative features with least amount of noise). When describing
estimated error rate per minimal row, treatment was retained as the only clinical metadata category in the model simulation that had the smallest level of
estimated error (closest to the < 10% mark for significance)
*: the cut off value of 25 reads was chosen for further analysis, because its error rate is closest to 10%
Fig. 2 Beta diversity analysis of the oropharyngeal microbiomes of non-azithromycin-treated samples, azithromycin-treated samples and washout
samples. Legend: The Principal Coordinates Analysis plot using the phylogenetic-based unweighted UniFrac algorithm for the comparison of the
oropharyngeal microbiomes of the azithromycin (AZ)-treated samples (green triangles) with those of the non-AZ-treated samples (blue squares)
and those of the washout samples of the 8 AZ-treated patients (red dots). Green triangles: AZ-treated samples: V3 and V6 of the 8 AZ-treated
subjects (n = 16). Blue squares: non-AZ-treated samples: all 20 samples of the 5 placebo-receiving subjects and V2 samples from the 8 AZ-treated
subjects (n = 28). Red dots: washout samples of the AZ-treated patients: V7 of the 8 AZ-treated patients (n = 8). Each group of dots of the
same patient is labeled with the patient number. Group color corresponds to non-treated patients (purple), AZ-treated patients (yellow)
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increases during treatment and even more so after
the washout period, but this is a bias, mainly due to
the observations in one patient (patient 122).
At the genus level, Streptococcus and Prevotella were
the most abundant genera in both the treated and un-
treated samples (Fig. 3b). The genus Fusobacterium is
more abundant in the pre-and post-treatment samples
(Fig. 3b), which confirms the observations at the phylum
level (Fig. 3a).
Crude analysis of the data, indicated that, of the 59
abundantly present OTUs, Streptococcus salivarius (the
fifth most abundant species at 4.13%) increased in all 8
AZ-treated patients, with a median 4.9-fold increase,
when comparing on-treatment (V3) with pretreatment
(V2) samples. To the contrary, OTU numbers 942 and
1071, that both correspond to HOT entry 222, i.e. Lepto-
trichia wadei (the seventh most abundant species at
3.86%), decreased in 7 out of the 8 AZ-treated patients,
with a median 5.0-fold decrease.
In conclusion, the most prevalent species, except for S.
salivarius and L. wadei, representing 81.76% of the oro-
pharyngeal microbiome, were overall little affected by
azithromycin treatment.
Boruta feature selection (Fig. 4) was used to look for
features that differed significantly between the treated
and untreated samples (at a cut off value of a minimum
of 25 reads per OTU). A HOMD search was used to ob-
tain species-level identification of the resulting OTUs
(Additional file 4). Boruta feature selection confirms the
conclusions that could be drawn from observing the raw
data, namely that S. salivarius (HOT-755) increases due
to AZ treatment (Fig. 4), whereas the species L. wadei
(HOT-222) significantly decreases with AZ treatment.
Also Actinomyces sp. (HOT-172), Leptotrichia spp.
(HOT-417 and HOT-225), Leptotrichia hofstadii (and
HOT-224) and Fusobacterium nucleatum (HOT-200)
significantly decrease with AZ treatment (Fig. 4 and
Additional file 4).
Discussion
The oral microbiome has been shown to be the primary
source of the healthy lung microbiome [18, 19] and in-
deed culture-independent studies have confirmed that
the microbiome of the lungs more closely resembles that
of the oropharynx than it does for instance that of other
possible source communities, such as inhaled air and the
nasopharynx [17–21]. This makes the oropharynx a
valuable proxy for the lung microbiome, which requires
less invasive techniques for sampling.
In this study, we assessed the microbiome composition
of the oropharynx of 13 asthmatic patients and found
the most abundant phyla to be the Firmicutes, Bacteroi-
detes, Fusobacteria, Proteobacteria and Actinobacteria
(in descending order) and the most abundant genera to
be Prevotella (P. melaninogenica: 15.17% of all reads, P.
pallens: 1.99% and P. nigrescens: 1.42%) and Streptococ-
cus mitis group (S. mitis/pneumoniae: 10.68%, S. para-
sanguinis: 6.84%, S. infantis: 0.95%, S. australis: 0.57%).
P. melaninogenica and S. mitis/pneumoniae were the
most abundant species, with both species together
accounting for 25.8% of the reads. The asthma patients
were colonized by the same phyla and genera that are
commonly found in the oropharynx of healthy
a b
Fig. 3 Taxonomic abundance comparison between azithromycin (AZ)-treated, non-AZ-treated and washout samples. Legend: Prevalence of the
most abundant phyla a and genera (b) in the oropharyngeal cavity for the AZ-treated (n = 16), non-AZ-treated (n = 28) and washout (visit 7, after
treatment, n = 8) samples. Taxonomic classification was made by means of the RDP classifier
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individuals, which has previously been characterized
using culture-independent methods.
Lemon et al. [36] and Hilty et al. [37] determined the
composition of the oropharyngeal microbiome of healthy
individuals, using a gene clone library and found the phyla
Firmicutes, Proteobacteria and Bacteroidetes to be the
most prevalent. Lemon et al. [36] confirmed these findings
with a 16S rRNA gene microarray. Also pyrosequencing
of the 16S rRNA gene indicated that the healthy orophar-
ynx is mainly colonized by the phyla Firmicutes, Actino-
bacteria, Bacteroidetes, Fusobacteria, candidate division
TM7 and the genera Actinomyces, Fusobacterium, Lepto-
trichia, Neisseria, Prevotella, Streptococcus and Veillonella
[38–41]. In addition, Segata et al. [40] showed that the
microbiomes of saliva, tongue, tonsils, and throat (back
wall of oropharynx) formed a group distinct from that of
the microbiomes of the buccal mucosa/keratinized gin-
giva/hard palate group, the sub- and supra-gingival plaque
group and the stool.
Hilty et al. [37] found the oropharyngeal microbial
composition of healthy controls to be comparable to
that of their asthmatic study population and Park et
al. [42], using 16S rRNA gene pyrosequencing, ob-
served no significant differences between asthma and
COPD patients. Park et al. [42] reported that Pseudo-
monas spp. and Lactobacillus spp. were dominantly
present in their asthmatic and COPD study popula-
tion, but this was not the case in our study nor in
that of Hilty et al. [37]. These different results could
be due to a difference in the study populations, i.e.
South Koreans [42] vs. Western populations (Hilty et
al. [37], this study). The possibility of important geo-
graphical variation between oral microbiomes is illus-
trated by a study performed by Zaura et al. [43]
where the salivary microbiomes were determined in a
Swedish and a British population. Interestingly, the
authors found that the predominant taxa in the
Swedish saliva samples were Prevotella spp. and a
Fig. 4 Relative abundance of bacterial taxa associated with the azithromycin (AZ)-treated vs. non-AZ-treated samples. Legend: The relative abundance
refers to how common or rare a species is relative to other species in the oropharyngeal microbiome of the entire sample population (n = 44).
Supervised (machine) learning with definition by randomForest and confirmation by Boruta feature selection (at cut off-value 25) enabled
visualization of bacterial taxa associated with the AZ-treated (visits V3 and V6, n = 16) vs. non-AZ-treated samples (visit V2 from all samples
and placebo samples, n = 28). The list is sorted first by Mann–Whitney U score followed by the largest disparity in medians between the
No treatment group and the Treatment group. Taxa represent the lowest taxonomic depth that is labeled by RDP Classifier (at ≥ 80%
bootstrap cut off). Boxes represent the first quartile, median, and third quartile of the distribution of OTUs for each treatment group.
Empty circles represent outliers that are 1.5x greater than the respective interquartile ranges. The species level identification of the Boruta
feature selection results were obtained through The Human Oral Microbiome Database (HOMD) Blast Search Tool
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Porphyromonas species, as opposed to Streptococcus
spp. and Rothia spp. in the British saliva samples.
A recent oropharyngeal microbiome sequencing study
by Castro-Nallar et al. [41] demonstrated that Lactoba-
cillus spp., more specifically L. gasseri, were relatively
more abundant in the oropharyngeal microbiome of
schizophrenia patients, but overall they reported the
presence of the same key members as established in
other studies.
Interestingly, Chlamydophila pneumoniae and Myco-
plasma pneumoniae were not recovered in this study
or the studies mentioned above, although both species
have been detected from patients with acute asthma
exacerbations [6–8].
The effect of macrolides on the (oro) pharyngeal
microbiome has been studied previously.
Malhotra-Kumar et al. [22] found that short-term
treatment with macrolides, i.e. clarithromycin and azi-
thromycin (AZ), induces a significant increase in
macrolide-resistant pharyngeal streptococci in healthy
volunteers. The COPD Clinical Research Network study
[10] performed a randomized trial where the subjects
were randomly assigned to receive AZ, at a dose of
250 mg daily (570 participants), or placebo (572 partici-
pants). They established an increased incidence of
macrolide resistant streptococci in the nasopharyngeal
microbiome as well. Recently, Zaura et al. [43] studied
the effect of the widely used antibiotics clindamycin, cip-
rofloxacin, amoxycillin and minocycline on the salivary
and fecal microbiome and found that the salivary micro-
biome is far more resilient toward the exposure to
antibiotics than the fecal microbial community. Further-
more, the authors noted that minocycline, amoxycillin
and clindamycin enhanced the prevalence of resistance
genes, such as the erythromycin resistance methylase
(Erm) and tetracycline efflux pump genes, in both the sal-
ivary and fecal microbiome [43]. These genes both cause
resistance to the macrolides AZ and erythromycin [44].
In the present study, we assessed the effect of long
term treatment (6 months) with AZ and the effects on
microbiome composition one month after treatment.
The phylum of the Firmicutes was positively affected by
the AZ treatment and more specifically the species
Streptococcus salivarius increased in AZ-treated samples.
This confirms the observation in the study of Brusselle
et al. [12], from which the samples for this study were
collected, that long-term treatment with AZ was associ-
ated with an increased proportion of macrolide-resistant
oropharyngeal streptococci (not further specified to the
species level). In contrast, the phylum Fusobacteria,
more specifically Fusobacterium nucleatum (HOT-200),
and the genus Leptotrichia, more specifically Leptotri-
chia spp. (HOT-417 and HOT-225), L. wadei (HOT-
222) and L. hofstadii (HOT-224), and Actinomyces sp.
(HOT-172) were significantly decreased within the AZ-
treated samples.
In the washout samples one month after the end of
the treatment (V7 samples), it could be observed that
the Firmicutes and Fusobacteria were evolving back to
their pre-treatment status. Interestingly, the oropharyn-
geal microbiome of 4 of the 8 treated patients regained
their initial composition within one month after the
treatment. The present study has some weaknesses, al-
though the number of samples (n = 52) was large, the
number of patients (n = 13) was low, which could have
influenced the random Forest classification estimated
error rates (Table 2). However, there were no obvious
differences in patient characteristics between the sub-
jects included in this substudy as compared with those
who were not included. There were no extraction con-
trols and/or negative controls of the sampling procedure
used in this study, which poses a possibility of contami-
nants remaining undetected and influencing the results
obtained. However, our results of the non-treated sam-
ples concurred with those of earlier studies of the oro-
pharyngeal microbiome [38–41].
Conclusion
This study confirmed the overall composition of the oro-
pharyngeal microbiome in patients with severe asthma
and confirmed that this overall composition does not
differ substantially from that of the healthy population.
Only 13 species made up 65% of the deep sequencing
reads, of which two (Prevotella melaninogenica and
Streptococcus mitis/pneumoniae) accounted for 25,85%
of the reads. We found that long term treatment
(6 months) with azithromycin increased the species
Streptococcus salivarius approximately 5-fold and
decreased the species Leptotrichia wadei approximately
5-fold. Four of the 8 patients regained their initial com-
position within one month after cessation of the treat-
ment. Long term azithromycin treatment may have long
term effects on the composition of the oropharygeal
microbiome in half of the patients, but this finding
should be confirmed by further studies.
Additional files
Additional file 1: Baseline characteristics for the AZISAST-trial (XLS 26 kb)
Additional file 2: Raw data, including read counts and sequences, of
the 59 OTUs represented by 0.2% or more of the total number of reads.
Species level identification was obtained through the HOMD database
Blast search tool. (XLS 100 kb)
Additional file 3: Beta diversity analysis of the oropharyngeal
microbiomes of the azithromycin-treated patients: visit 2 versus visit
3. Legend: The Principal Coordinates Analysis plot using the
phylogenetic-based unweighted UniFrac algorithm for the comparison of
the oropharyngeal microbiomes of the non- azithromycin (AZ)-treated
samples with the oropharyngeal microbiomes of the AZ-treated
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samples. Blue dots: non-AZ-treated samples (n = 8): the Visit 2 samples
(before treatment) of the 8 AZ-treated subjects. Green dots: AZ-
treated samples (n = 8): Visit 3 samples (one month after the start of
treatment) of the 8 AZ-treated patients. Each dot is labeled with the
patient number and visit code. (PPTX 66 kb)
Additional file 4: Raw data, including read counts and sequences, of
the 15 OTUs in Fig. 4 (bacterial taxa associated with the AZ-treated vs.
non-AZ-treated samples) that resulted after Supervised machine learning.
Species level identification was obtained through the HOMD database
Blast search tool. (XLS 36 kb)
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